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Genetic epidemiological studies have been instrumental in guiding
efforts to map disease susceptibility genes, firstly, by identifying
diseases with marked familial aggregation and, secondly, by
guiding the selection of appropriate families for linkage or muta-
tion analysis. This approach has been successful in, for example,
breast cancer where segregation analysis suggested the presence of
a high-risk, low-frequency allele that explained a part of the
familial aggregation of the disease, eventually confirmed by the
identification of BRCA1 and BRCA2 (Szabo and King, 1997). For
prostate cancer, segregation analysis suggested dominant pattern
of inheritance but the higher prostate cancer risks between affected
brothers than father–son pairs suggested the presence of a reces-
sive or X-linked component (Monroe et al, 1995). Both autosomal
and X-linked prostate cancer susceptibility loci have been mapped
by linkage (Narod, 1999). A putative X-linked testis cancer
susceptibility locus has also recently been mapped (Rapley et al,
2000). Even though many systematic studies have been carried out
on familial aggregation of cancer (Goldgar et al, 1994; Carstensen
et al, 1996; Easton et al, 1996; Peto et al, 1996; Hemminki et al,
1998), specific analysis of risks to siblings has been limited to
studies on particular cancer sites and only some of the commonest
cancers have been examined (Carstensen et al, 1996; Easton et al,
1996; Peto et al, 1996). Risks to siblings are of interest since high
risks, in comparison with risks to parents or offspring, may
indicate recessive or X-linked components to the disease. 
Here we use the nation-wide Swedish Family-Cancer Database
on 9.6 million individuals and more than 700 000 primary cancers
to assess systematically the offspring and sibling risks for common
cancers. The family dataset is unique in size, coverage and longi-
tudinal time span. 
SUBJECTS AND METHODS 
The Swedish Family-Cancer Database includes persons born after
1934 with their biological parents (Hemminki and Vaittinen, 1998;
Hemminki et al, 1998). Cancers were retrieved from the nation-
wide Swedish Cancer Registry covering the period 1958 to 1996;
thus, the maximum age at last follow-up for offspring was 61. A
4-digit diagnostic code according to the 7th revision of the
International Classification of Diseases (ICD-7) was used. In the
tables, the category ‘colorectal’ is defined by ICD-7 codes 153 and
154.0 (i.e. excluding anus) and ‘lung’ by codes 162 and 163. 
Age-specific incidence rates to offspring of affected parents
(‘offspring risks’), were calculated in 5-year diagnosis age bands
from 10 to 61 years. Standardized incidence ratios (SIRs) were
calculated as the ratio of observed (O) to expected (E) number of
cases. The expected numbers were calculated from age-, sex- and
tumour type-standardized rates (Esteve et al, 1994). Confidence
intervals (95% CI) were calculated assuming a Poisson distribu-
tion (Esteve et al, 1994). 
Risks to full siblings of affected individuals were calculated in a
similar manner; however, because individuals may have more than
one affected sibling, risks to siblings may be defined in several
ways. We considered two definitions, referred to as the ‘cohort
method’ and the ‘multiple-counting method’. In the cohort method
one simply defines a cohort of individuals with at least one
affected sibling, and computes the incidence rates in this cohort
over the period 1958 to 1996 as before. Note that in a family with
two or more affected siblings, each affected individual is included
in the cohort (as the sibling of an affected individual). In the
multiple-counting method by contrast, one considers all possible
pairs of siblings, and computes the incidence in a ‘cohort’ of indi-
viduals whose co-sibling is affected. The methods are formally
identical for families with at most two siblings, and for families
with only one affected individual. However, under the multiple
counting method, an individual with n affected siblings will be
included n times in the cohort, rather than once in the cohort
method. Thus the incidence rates in the cohort method are given
by the formula: 
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And in the multiple counting method by the formula: 
Where nk is the number of affected individuals with k affected
siblings, pk the number of person-years contributed by unaffected
individuals in families with k affected siblings, and yk the number
of person-years contributed by affected siblings in families with k
affected siblings, in the relevant age/sex/period category. The
corresponding reference rates (for both methods) are given by: 
Although more complex, the multiple counting method has the
theoretical advantage that it provides an unbiassed estimate of the
risk to the siblings of a specified affected individual, regardless of
the family size distribution (provided that risks are not related to
family size), and that this parameter will be equal to the offspring
risk under any additive genetic models (and, to good approxima-
tion, under dominant models). Under the cohort method, the rela-
tive risks would be expected to decrease with family size, and can
be slightly lower than the offspring risks under additive models. In
practice, however, we found that the relative risk estimates given
by the two methods were almost identical, and only those given by
the cohort method are shown. An additional complication in the
computation of risks to siblings is that, since it is based on
complete ascertainment of sibships with affected individuals,
families with multiple affected individuals are ascertained
multiple times, so that the observed cancers in the cohort are not
independent. Thus a family with 2 affected siblings will contribute
2 observed cancers, whereas it is in fact only one independent
event, leading to an inflated variance of the relative risk. To correct
for this, we approximated the variance of the log (relative risk) by
1/(N-M), rather than by 1/N, where N is the total number of
cancers and M is the number of ascertained families (Goldgar et al,
1994). 
RESULTS 
Table 1 shows offspring and sibling risks for 13 common cancer
sites. The SIRs for both offspring and sibling risks were signifi-
cantly greater than 1 for all cancer sites. The offspring risks range
from 4.09 for testis to 1.55 for urinary bladder. The sibling risks
were greater than the offspring risks for 12 of the 13 sites, the sole
exception being ovarian cancer. The difference in risk reached
statistical significance for cancers of the colorectum (P < 0.001),
breast (P = 0.024), prostate (P = 0.003), testis (P = 0.04) and
kidney (P = 0.012), and for melanoma (P = 0.019) and leukaemia
(P = 0.042). After ovary, breast cancer had the smallest
sibling:offspring risk ratio (1.15). The ratio was highest for kidney
(2.55), testis (2.22), bladder (2.01) and prostate (1.95). There is no
statistically significant sex difference (i.e., 95% CIs overlapped for
SIRs of male and female offspring) for any of the comparisons
shown in Table 1 but the largest difference was noted for bladder
cancer. Among the 12 affected sibs, only one was female, giving a
SIR of 4.06 (95% CI 2.02–7.30) for male offspring and 1.07
(0–6.17) for female offspring. 
For sibling risks we separated those who had an affected parent
in order to identify possible rare dominant gene effects. Higher
SIRs were observed in siblings with an affected parent, compared
with those with unaffected parents, for all sites except cervix, testis
and bladder where no affected sibling pairs with an affected parent
were present. SIRs were particularly high for colorectal cancer
(20.46), ovary (31.10), prostate (31.35), kidney (28.90) and
leukaemia (32.08). 
DISCUSSION 
The observed excess risks of cancer in siblings could be due to
either genetic or environmental causes, or both. We have assessed
the effect of shared environment in adulthood from this Database
by comparing cancer risks between spouses (Hemminki and Dong,
2000; Hemminki et al, 2000). Among the cancers discussed here,
significant spouse concordance was only found for stomach and
lung cancers, and melanomas if diagnosed at a young age.
Siblings, however, share lifestyle risk factors in childhood and this
may be a cause of some of the increased sibling risks, as compared
with offspring risk. In a recent twin analysis by Lichtenstein et al
(2000), based on a combined cohort of twins from Sweden,
Denmark and Finland, risks to monozygotic (MZ) twins of cancer
cases were more than twice the risk to dizygotic (DZ) twins for
prostate, ovarian and bladder cancer, although the numbers (except
for prostate cancer) were small. If one assumes that the distribu-
tion of shared environmental factors will be similar in MZ and DZ
twins, this suggests that environmental factors are unlikely to be
the main determinants of familial risk, at least for these cancer
sites. 
Another possible factor leading to higher sibling relative risks is
that some familial relative risks are age-dependent. In this study,
all affected siblings must be diagnosed under age 61, whereas the
affected parents used to determine offspring risks may be older. If
familial relative risks decline with age, the sibling relative risks
will be higher than offspring risks even if the age-specific risks are
equal. This may be part of the explanation for the effects of
colorectal and prostate cancer. At present, there are too few data to
allow for the age-specific effects adequately in this cohort. 
If the higher sibling risks are genetic, they could be due either to
autosomal recessive or X-linked recessive genes. An X-linked
susceptibility allele would be predicted to cause an increased risk
only in male siblings of male cases, whereas autosomal recessive
alleles affect both sexes. In none of the previous analysis of
offspring–parents risks from this Database nor in the present
analysis have we observed significant sex differences in familial
relative risks in the cancers that affect both genders, with the
possible exception of bladder cancer noted above, suggesting that
X-linked recessive effects are likely to be weak. In male-specific
cancers of testis and prostate, it would not be possible to distinguish




































+For most of the cancer sites, the sibling risks were substantially
higher when a parent was also affected. This effect was particu-
larly marked for colorectal, ovarian, prostate and kidney cancer,
and for melanoma and leukaemia, although all these observations,
except for colorectal cancer, are based on small numbers. These
high risks are consistent with the effects of a highly penetrant
dominant susceptibility gene responsible for a proportion of cases.
The observed familial risks for ovarian cancer are mostly due to
mutations in BRCA1 and BRCA2 (Antoniou et al, 2000).
Interestingly, the high relative risk in siblings with an affected
mother is not observed for breast cancer, consistent with previous
observations that BRCA1/2 make only a minor contribution to
familial breast cancer (Peto et al, 2000). 
The sibling:offspring risk ratio was close to 1 for both ovarian and
breast cancer, suggesting that the main genetic effects are dominant
or additive. For these cancers our sibling and offspring risks are in
line with comprehensive meta-analyses of the published literature
(Pharoah et al, 1997; Stratton et al, 1998). For colorectal, lung and
endometrial cancer, and for lymphoma and leukaemia, the ratio was
around 1.5, suggesting some recessive or X-linked component. At
the other extreme kidney, bladder, testis and prostate cancer show a
high sibling:offspring risk ratio. The high sibling risk for prostate
cancer is consistent with the observation that some multiple case
prostate cancer families show linkage to a region on chromosome
Xq, while other families appear to be linked to autosomal loci. (Xu
et al, 1998; Grönberg et al, 1999; Narod, 1999). A particularly high
risk to MZ twins of prostate cancer cases was observed by
Lichtenstein et al (2000) (relative risk 12.3 vs 3.1 for DZ twins),
which might suggest a recessive component. An X-linked locus has
also recently been mapped for testicular cancer (Rapley et al, 2000).
The most important susceptibility gene for kidney cancer is the
VHL gene, responsible for the von Hippel Lindau syndrome
(Fearon, 1997); this, however, is unlikely to be a major determinant
of familial kidney cancer. No major susceptibility genes for bladder
cancer have yet been identified, although mutations in the mismatch
repair genes, Rb and p16 are associated with some increased risk. 
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Table 1 Offspring and sibling risks for concordant cancers in families 




O E SIR 95% CI with same cancer O E SIR 95% CI Offspring 
No 38 14.0 2.71 1.73 4.25 1.47 
Colorectum Yes 30 1.5 20.46 12.33 33.94
429 232 1.85 1.67 2.03 Total 68 15.5 4.39 3.14 6.14 
No 11 4.5 2.46 1.02 5.91 1.47 
Lung Yes 3 0.3 11.07 1.56 78.59 
125 74.4 1.68 1.40 2.00 Total 14 4.7 2.96 1.41 6.21 
No 419 199.9 2.10 1.83 2.40 1.15 
Breast Yes 42 14.6 2.88 1.88 4.41 
1512 828 1.83 1.73 1.92 Total 461 214.5 2.15 1.89 2.45 
No 28 12.4 2.27 1.34 3.83 1.23 
Cervix Yes 0 0.3 
86 46.5 1.85 1.48 2.28 Total 28 12.6 2.22 1.31 3.75 
No 12 3.0 3.94 1.77 8.77 1.65 
Endometrium Yes 0 0.1
69 28.9 2.39 1.86 3.03 Total 12 3.1 3.82 1.72 8.50
No 12 6.6 1.83 0.82 4.07 0.66 
Ovary Yes 4 0.1 31.10 7.78 124.4 
95 34.3 2.77 2.24 3.38 Total 16 6.7 2.39 1.20 4.78 
No 4 0.8 5.00 1.25 19.99 1.95 
Prostate Yes 6 0.2 31.35 10.11 97.20 
167 65.2 2.56 2.18 2.98 Total 10 1.0 10.09 4.20 24.24 
No 38 4.2 9.07 5.79 14.22 2.22 
Testis Yes 0 0.0 
12 2.9 4.09 2.13 7.20 Total 38 4.2 9.05 5.77 14.19 
No 10 2.3 4.38 1.82 10.52 2.54 
Kidney Yes 2 0.1 28.90 4.07 205.2 
45 26.2 1.72 1.25 2.30 Total 12 2.4 5.10 2.29 11.35 
No 12 3.9 3.11 1.40 6.92 2.01 
Bladder Yes 0 0.1 
69 44.6 1.55 1.20 1.96 Total 12 4.0 3.02 1.36 6.72 
No 107 30.0 3.56 2.72 4.66 1.37 
Melanoma Yes 7 0.6 11.12 3.59 34.48 
189 72.6 2.60 2.24 3.00 Total 114 30.7 3.72 2.86 4.83 
No 34 14.4 2.36 1.47 3.80 1.47 
Lymphoma Yes 2 0.3 6.93 0.98 49.20 
106 66.2 1.60 1.31 1.94 Total 36 14.7 2.45 1.54 3.89 
No 24 8.2 2.93 1.66 5.16 1.59 
Leukaemia 61 33.1 1.84 1.4 2.37 Yes 4 0.1 32.08 8.02 28.3
Total 28 8.3 3.37 2.00 5.69 Cancer models 391
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In conclusion, these results raise the possibility that recessive or
X-linked susceptibility genes, as yet unidentified, may be impor-
tant for some common cancers. Such genes will not be mappable
by linkage studies in large families, but may be identifiable
through large series of affected sibling pairs or association studies. 
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